The company is also working with pharmaceutical companies to leverage its database for drug development and marketing. LinkDoc empowers evidence-based, personalized cancer treatment in China by providing doctors with valuable analytics derived from its oncology database. Through its presence in more than 200 of China's major oncology hospitals, LinkDoc has built a rich repository of cancer patients' medical records and comprehensive clinical data and continues to expand its reach in terms of cancer types, data scope and patient base. Lung cancer, which LinkDoc has made a key area of focus, has emerged as a particularly prevalent disease.
Cancer cases and cancer-related deaths are expected to reach an annual rate of 4.0 million and 3.5 million in China by 2020, respectively, according to estimates by the World Cancer Society.
LINKDOC DATA SCIENTIST SERIES
Ally Bridge Group (ABG) Expands Personalized Medicine Portfolio, Invests in LinkDoc Technology Limited, China's Oncology Big Data CompanyĪlly Bridge Group ("ABG"), a leading cross-border healthcare-focused investment group, is pleased to announce the completion of its Series B investment into LinkDoc Technology Limited, a leading oncology-focused big data company in China, alongside other leading Chinese and international investors.Ĭancer is China's leading fatal disease, with a rapidly growing patient population and burgeoning treatment and management expenditures.
0 kommentar(er)
